Clinical trials
Metastatic Esophageal Squamous Cell Carcinoma clinical trials
Below are recruiting metastatic esophageal squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 101 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07403136RecruitingPhase 2
Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07359417RecruitingPhase 1
MR-guided radiation boost for esophageal cancer
This trial tests whether giving a higher dose of radiation to the main tumor, guided by MRI scans, can improve treatment for a type of esophageal cancer called squamous cell carcinoma. You would first receive standard chemoradiation followed by surgery.
Utrecht, UtrechtAges 18 years+ - NCT07484724RecruitingPhase 2
JS212 combination therapy for advanced esophageal cancer
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07463573RecruitingPhase 3
New drug vs chemotherapy for advanced esophageal cancer
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07290010RecruitingPhase 2
Iparomlimab plus chemotherapy for advanced esophageal cancer
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with chemotherapy as a first treatment for advanced esophageal squamous cell carcinoma. It aims to see if this combination is safe and effective for people whose cancer cannot be removed by surgery or has spread.
Shijiazhuang, HebeiAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07263919RecruitingPhase 2
Chemo plus cadonilimab before surgery for esophageal cancer
This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.
Xi'anAges 18–75 - NCT07266480RecruitingPhase 2
Adalimumab after surgery for esophageal cancer
This trial tests whether adding adalimumab (a medicine that helps the immune system) after surgery can prevent esophageal cancer from coming back. It's for people who have already had their cancer completely removed by surgery.
Shijiazhuang, HebeiAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Bullhead City, ArizonaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07205731RecruitingPhase 2
Tislelizumab for older adults with advanced esophageal cancer
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
Annecy, Epagny Metz-TessyAges 70 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
La Jolla, CaliforniaAges 18 years+ - NCT07061704RecruitingPhase 1/Phase 2
Oncolytic virus trial for esophageal cancer
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
Chengdu, SichuanAges 18–80 - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT07000253RecruitingPhase 2
Timing of local treatment for limited metastatic stomach or esophageal cancer
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
AmsterdamAges 18 years+ - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+
Hear when a new Metastatic Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic esophageal squamous cell carcinoma?
- Yes. Clin2 currently lists 101 recruiting metastatic esophageal squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic esophageal squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic esophageal squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Esophageal Squamous Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Metastatic Hypopharyngeal Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.